Researchers have made several impressive advances in gastrointestinal medicine in recent years, including the use of fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infection. Following the success of that approach, researchers have been evaluating FMT for the treatment of other conditions, with one team recently conducting the first randomized controlled trial of FMT to treat inflammatory bowel disease (IBD).
New guidelines have been issued in relation to the management of irritable bowel syndrome and chronic idiopathic constipation. The updated guidelines were published as a supplement to the August issue of the American Journal of Gastroenterology.
Immune cells responsible for intestinal movement may be the key to an effective treatment for irritable bowel syndrome.
Although tumor necrosis factor inhibitors have dramatically improved management strategies for autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease, the biologic agents also pose a number of significant side effects that physicians must consider.
Although small-bowel capsule endoscopy is often used to evaluate unexplained abdominal pain, a new analysis has found the procedure’s diagnostic yield is limited.
Salmonella-induced gastroenteritis during childhood is associated with increased risk of irritable bowel syndrome (IBS), according to a study published in the July issue of Gastroenterology.